GTBP — what changed in the latest 10-Q
A section-by-section comparison of GTBP's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-14 vs the prior 10-Q · 2026-05-15
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +7 | −8 | ~11 | 21 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 8 |
| Legal proceedings | Text added/removed | 0 | 0 | ~1 | 2 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-14
Research and development expenses remained relatively flat for the six months ended June 30, 2026 compared to the same prior year period.
Research and development expenses relate to our continued licensing, development, production, and clinical trials of our most advanced TriKE® product candidates GTB-3650 and GTB-5550 along with the progression on other promising candidates. In late June 2024, we received clearance from the FDA with …
Selling, general and administrative expenses increased by approximately $2.3 million and $3.8 million for the three and six months ended June 30, 2026, respectively, compared to the same prior year periods, primarily due to an increase in marketing expenses, and to a lesser extent, legal and consult…
The Greenshoe Rights connected to the Series L Preferred Stock issued in the May 2025 equity offering contained a pricing reset feature that required classification as a liability and marked to market at each reporting date as required under GAAP.
Net loss decreased by approximately $25.7 and $23.6 million for the three and six months ended June 30, 2026, respectively, compared to the same prior year periods, primarily due to the prior year loss on initial recognition of Greenshoe Rights liability of $28.7 million which did not occur in the c…
Text removed vs the prior filing · source: 10-Q · 2026-05-15
Research and development expenses relate to our continued licensing, development, production, and clinical trials of our most advanced TriKE® product candidates GTB-3650 and GTB-5550 along with the progression on other promising candidates. In late June 2024, we received clearance from the FDA with …
Selling, general and administrative expenses increased by approximately $1.6 million for the three months ended March 31, 2026, compared to the same prior year period, primarily due to an increase in marketing expenses, and to a lesser extent, legal fees.
Interest income decreased by $35,000 for the three months ended March 31, 2026 compared to the same prior year period, due to greater money market fund balances.
The change in fair value of warrant liability decreased by $115,000 for the three months ended March 31, 2026 compared to the same prior year period, primarily due to a relative decline in the Company’s stock price at March 31, 2026 as compared to the same prior year period.
Net loss increased by approximately $2.1 million for the three months ended March 31, 2026 compared to the same prior year period, primarily due to an increase in selling, general and administrative expenses of approximately $1.5 million, and a decrease in other income of approximately $1.1 million,…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice